When: Tuesday, April 11, 2017 from 12:30 - 3:00 p.m.
Lunch and Networking from 12:00 - 12:30 p.m.
This workshop will focus on the practical considerations of moving cell therapies into clinical trials. We encourage all OIRM Disease Teams, both funded and non-funded to attend this workshop. Travel subsidy will be provided to support in-person attendance. Please contact email@example.com for more information.
Patrick Bedford, Manager of Clincial Translation and Regulatory Affairs at CCRM, is speaking on the regulatory environment involving the use of IPSC in clinical trials and potential hurdles as these cells move towards the clinic.
Emily Titus, Director of Technology Development at CCRM, will address considerations for cell manufacturing and scale-up production of GMP-grade IPSC.
David Courtman, Senior Investigator at OHRI and Director of the Biotherapeutics Core Facility, will provide lessons learned during the process of regulatory approval and implementation of a cell-manufacturing platform to support MSC production for use in cell therapies.